Melanoma Archives - Patient Worthy

source: shutterstock.com

Rare Community Profiles: Fighting for Women’s Fertility: How Amanda Translated Her 3 Cancer Diagnoses into Empowerment

Post author:Jessica Lynn
Post published:January 18, 2024
Post category:Breast Cancer Melanoma

Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…

source: shutterstock.com

Melanoma Lung Metastases: How Macrophages Evolve

Post author:Rose Duesterwald
Post published:January 12, 2024
Post category:Melanoma

Macrophages play a crucial role in responding to injury or infection. Thomas Tapmeier, a researcher at Monash University and Oxford University, recently discussed a study he co-authored in MedicalXpress.…

Source: https://pixabay.com/en/syringe-kanuelle-vaccination-1574486/

STUDY: Keytruda + mRNA-4157 (V940) Vaccine Reduced Risk of Severe Melanoma Recurrence

Post author:Jessica Lynn
Post published:January 5, 2024
Post category:Melanoma

In an investor news release from December 2023, Moderna and Merck shared follow-up data from the Phase 2b KEYNOTE-492/mRNA-4157-P201 clinical trial. During the trial, researchers explored the impact of Keytruda…

Photo by Dave Adamson on Unsplash

The NFL’s My Cause My Cleats 2023: Lacing Up for Awareness with Players’ Personal Stories

Post author:Jessica Lynn
Post published:December 22, 2023
Post category:Alzheimer's disease Melanoma Rare Disease

During the NFL’s My Cause My Cleats initiative, passion and purpose collide on the field. This initiative embodies the profound bond between athletes and the causes that matter to…

Photo by National Cancer Institute on Unsplash

ICYMI: Opdivo Now Approved for Patients Aged 12+ with Surgically Resected Stage 2B-C Melanoma

Post author:Jessica Lynn
Post published:November 17, 2023
Post category:Melanoma

In the past, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) for different forms of cancer, such as non-small cell lung cancer (NSCLC) and melanoma. More recently,…

qimono / Pixabay

Can an Experimental mRNA Vaccine Prevent Melanoma Relapse?

Post author:Jessica Lynn
Post published:October 20, 2023
Post category:Melanoma

Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…

Photo courtesy of the Melanoma Research Alliance

Rare Community Profiles: Melanoma Research Alliance’s Marc Hurlbert Shares Milestone Achievement of RARE Registry for Acral and Mucosal Melanoma

Post author:Jessica Lynn
Post published:October 17, 2023
Post category:Melanoma

Rare Community Profiles Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…

source: shutterstock.com

A Preview of Potentially Historic FDA Approvals for 2023

Post author:Rose Duesterwald
Post published:August 26, 2023
Post category:Alzheimer's disease Amyloid Neuropathies Beta Thalassemia Beta Thalassemia Major Melanoma Sickle Cell Disease

The later part of 2023 will see decisions on drugs in four areas such as advanced melanoma, sickle cell disease, Alzheimer’s disease, and depression. BioSpace shines the spotlight on…

source: pixabay.com

Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?

Post author:Jessica Lynn
Post published:August 13, 2023
Post category:Melanoma Papillary craniopharyngioma

Each year, there are less than 600 new cases of papillary craniopharyngioma (PCP) diagnosed within the United States. While PCP typically has a good prognosis with treatment, treatment is…

Alexas_Fotos / Pixabay

Can We Leverage Fecal Transplants to Improve Melanoma Outcomes?

Post author:Jessica Lynn
Post published:July 27, 2023
Post category:Melanoma

It’s no secret that our gut health plays a formative role in our overall health. Over the past decade, more and more studies have examined how the gut microbiome impacts…

https://pixabay.com/en/american-football-football-sports-1666276/

INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)

Post author:Jessica Lynn
Post published:January 11, 2023
Post category:Melanoma

Before you read on, make sure to check out: Part 1 of our article: Green Bay Packers' Shemar Jean-Charles and Los Angeles Chargers' Storm Norton discuss why they raise Alzheimer's disease…

source: unsplash.com

RHOBH’s Teddi Mellencamp Discusses her Melanoma Surgery

Post author:Jessica Lynn
Post published:January 10, 2023
Post category:Melanoma

At 41 years old, Teddi Mellencamp has done many great things in her life. The daughter of singer-songwriter John Mellencamp, Teddi is a successful podcast host and a reality television…

PDPics / Pixabay

AVS100 Earns Orphan Drug Designation for Advanced Melanoma

Post author:Jessica Lynn
Post published:December 20, 2022
Post category:Melanoma Metastatic Melanoma

Currently, the standards-of-care for advanced/metastatic (stage III or IV) melanoma include immunotherapy, targeted therapy, and radiation. Some patients are given anti-PD-1 inhibitors. However, only around 20-30% of those living…

Biomarkers Found for Hyper-Progression of Melanoma after Immunotherapy

Post author:Rose Duesterwald
Post published:December 6, 2022
Post category:Melanoma

Inside Precision Medicine recently featured an article focusing on biomarkers that suggest the likelihood of drugs called checkpoint inhibitors to “backfire” during melanoma treatment. Checkpoint inhibitors are one of the…

source: unsplash.com

Considerations for Advanced Melanoma Targeted Therapies

Post author:James Moore
Post published:July 14, 2022
Post category:Melanoma

According to a story from AJMC, there are a number of factors in play when determining the path forward for the treatment of advanced melanoma. For this story, Dr. Omid…

The European Commission Has Approved Pembrolizumab (Keytruda) to Treat Resected Stage IIB and IIC Melanoma

Post author:Rose Duesterwald
Post published:July 12, 2022
Post category:Melanoma

According to a press release by Merck & Co. issued on June 24, the European Commission has approved the use of adjuvant Pembrolizumab to treat resected stage IIB/C melanoma. "Adjuvant"…

Source: https://pixabay.com/en/thumb-up-like-sign-hand-ok-good-441938/

An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma

Post author:Rose Duesterwald
Post published:April 22, 2022
Post category:Melanoma Rare Disease

Maria’s message is: “when in doubt, get a biopsy." Ten years ago, Maria Sylvia noticed a vertical streak on her thumbnail that at the time she thought was “cool." She…

cocoparisienne / Pixabay

FDA Approves First Ever Treatment for Uveal Melanoma

Post author:James Moore
Post published:March 10, 2022
Post category:Melanoma Uveal melanoma

According to a story from Biopharma Dive, the US Food and Drug Administration (FDA) has recently approved a treatment for a rare form of melanoma that affects the eyes, called…

source: pixabay.com

Relatlimab + Nivolumab Increase Survival in Metastatic Melanoma

Post author:Jessica Lynn
Post published:January 11, 2022
Post category:Melanoma Metastatic Melanoma

Over the last 10+ years, there have been extreme advances in the treatment of metastatic melanoma. In particular, researchers have sought to develop therapies which halted cancer progression and reduced…

dfuhlert / Pixabay

UV1 Earns Orphan Drug Status for Metastatic Melanoma

Post author:Jessica Lynn
Post published:December 10, 2021
Post category:Melanoma Metastatic Melanoma

On December 2, 2021, Ultimovacs ASA ("Ultimovacs") announced via news release that its universal cancer vaccine, UV1, received Orphan Drug designation from the FDA. UV1 is designed for those…

source: pixabay.com

Metastatic Melanoma: Chemotherapy and BRAF Oncogene Inhibitors

Post author:Rose Duesterwald
Post published:July 26, 2021
Post category:Melanoma Rare Disease

The primary cause of death in melanoma patients is widespread metastases. Currently, there is no cure in cases of relapse or in advanced stages. A recent article in Science…

source: pixabay.com

St. Jude’s Establishes Registry for Pediatric Melanoma

Post author:James Moore
Post published:July 8, 2021
Post category:Melanoma

St. Jude Children's Research Hospital has recently announced that its team of scientists have established a registry for pediatric melanoma. The goal is to use data from this registry for…

source: shutterstock

Rare Classroom: Metastatic Melanoma

Post author:James Moore
Post published:June 4, 2021
Post category:Melanoma Melanoma of the ciliary body

Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…

source: pixabay.com

Tebentafusp Improves Uveal Melanoma Survival Rates

Post author:Jessica Lynn
Post published:April 26, 2021
Post category:Melanoma

Over the last 50 years, doctors have been working to improve clinical outcomes for patients with a rare but aggressive form of ocular cancer: uveal melanoma. However, there has been…

geralt / Pixabay

Study Associates Alpha-synuclein with Melanoma and Parkinson’s

Post author:Jessica Lynn
Post published:April 13, 2021
Post category:Melanoma Parkinson's Disease

From April 5 - 30, the American Chemical Society meets to hold ACS Spring 2021, where chemistry professionals meet to discuss new research and knowledge in their field. During the…

Rare Community Profiles: Fighting for Women’s Fertility: How Amanda Translated Her 3 Cancer Diagnoses into Empowerment

Melanoma Lung Metastases: How Macrophages Evolve

STUDY: Keytruda + mRNA-4157 (V940) Vaccine Reduced Risk of Severe Melanoma Recurrence

The NFL’s My Cause My Cleats 2023: Lacing Up for Awareness with Players’ Personal Stories

ICYMI: Opdivo Now Approved for Patients Aged 12+ with Surgically Resected Stage 2B-C Melanoma

Can an Experimental mRNA Vaccine Prevent Melanoma Relapse?

Rare Community Profiles: Melanoma Research Alliance’s Marc Hurlbert Shares Milestone Achievement of RARE Registry for Acral and Mucosal Melanoma

A Preview of Potentially Historic FDA Approvals for 2023

Could Melanoma Drugs be Effective in Treating Papillary Craniopharyngioma (PCP)?

Can We Leverage Fecal Transplants to Improve Melanoma Outcomes?

INTERVIEWS: NFL Players Discuss the Rare, Chronic, and Underserved Causes that Mean the Most to Them (Pt. 3)

RHOBH’s Teddi Mellencamp Discusses her Melanoma Surgery

AVS100 Earns Orphan Drug Designation for Advanced Melanoma

Biomarkers Found for Hyper-Progression of Melanoma after Immunotherapy

Considerations for Advanced Melanoma Targeted Therapies

The European Commission Has Approved Pembrolizumab (Keytruda) to Treat Resected Stage IIB and IIC Melanoma

An Innocent-Looking Shadow on Her Thumbnail Turned Out to be Subungual Melanoma

FDA Approves First Ever Treatment for Uveal Melanoma

Relatlimab + Nivolumab Increase Survival in Metastatic Melanoma

UV1 Earns Orphan Drug Status for Metastatic Melanoma

Metastatic Melanoma: Chemotherapy and BRAF Oncogene Inhibitors

St. Jude’s Establishes Registry for Pediatric Melanoma

Rare Classroom: Metastatic Melanoma

Tebentafusp Improves Uveal Melanoma Survival Rates

Study Associates Alpha-synuclein with Melanoma and Parkinson’s

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

“Shades of Psoriasis”: Plaque Psoriasis and Sharing Your Story

Understanding RSV: Why Combatting Ethnic and Age-Related Health Disparities Could Improve Outcomes

We Need Equity and Diversity Within Rare Disease Research

DNA in Color: How Ronya Nelson is Working to Close the Diversity Gap in Genetics - Part 1

Bridging the Diversity Gap in Healthcare

Congratulations to the 2023 Recipients of the Diversity in Lupus Research Awards!

Welcome to Study of the Week. We go in-depth and select a study we think is of particular interest, discussing details, explaining its importance, who may be impacted and lots more!

Let’s Work Together!

Keep Up to Date

Learn More